List view / Grid view
Speaking at CPHI Frankfurt, Bruno Fabre underlined the importance of companies viewing the technology as a fundamental business capability, rather than “an afterthought”.
Scientific and commercial opportunity for pharma companies looking to source, co develop and manufacture traditional Chinese medicine (TCM).
The CDMO’s programme, presented at CPHI Frankfurt 2025, combines responsiveness to new demand and operational rigour without jeopardising supply.
Model offers mid market innovators and larger pharma companies tailored processes and scale capacity without compromising compliance.
This article delves into the key trends shaping drug delivery amid a surge of innovation, including advanced delivery systems and sustainability, and offers an outlook for the future of the sector.
This article explores how artificial intelligence (AI) is forming an essential pillar of staying competitive in pharmaceutical manufacturing, with its adoption ensuring greater efficiency of medicine production in this fast-evolving sector.
